Legacy Capital Group California, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Legacy Capital Group California, Inc.
- $287 Billion
- Q1 2025
A detailed history of Legacy Capital Group California, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Legacy Capital Group California, Inc. holds 9,554 shares of APLS stock, worth $185,252. This represents 0.07% of its overall portfolio holdings.
Number of Shares
9,554
Previous 7,195
32.79%
Holding current value
$185,252
Previous $230 Million
8.99%
% of portfolio
0.07%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$239 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$237 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$231 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$196 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$187 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.13B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...